SVT-40776 in Patients Suffering From Overactive Bladder Syndrome

Status:
Completed

Trial end date:
2007-09-01

Target enrollment:

Participant gender:

The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine

Phase 2

Salvat